Introduction Access and funding for newly approved treatments for non-small cell lung
cancer (NSCLC) are often dependent on Health Technology Assessment (HTA) involving …

Background Trustworthy educational information for patients is critical for increasing their
knowledge base and preparing them for shared decision making with clinicians. As the …

Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients
with head and neck squamous cell carcinoma (HNSCC). Methods: Systematic review and …

OBJECTIVE. The purpose of this review is to elucidate the mechanisms, types, and clinical
significance of molecular targeted therapy (MTT) and immune checkpoint inhibitors (ICIs) …

Objective Meta analysis was used to compare the efficacy and safety of immune checkpoint
inhibitor and docetaxel in the treatment of non-small cell lung cancer. Methods CNKI, CBM …

Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death
protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial …

Recently, pretreatment with immune checkpoint inhibitors (ICIs) has been shown to enhance
the therapeutic effects of the combination therapy of ramucirumab (RAM) and docetaxel …

Decisional conflict might occur during shared decision-making (SDM) because
immunotherapy is a rather novel treatment option for patients with cancer. To explore the …

基于TCGA数据库筛选和鉴定肺腺癌免疫治疗临床获益关键基因齐晓光, 祁春艳, 秦博宇, 胡毅,
韩为 Page 1 基于TCGA数据库筛选和鉴定肺腺癌免疫治疗临床获益关键基因 齐晓光, 祁春艳 …